Skip to main navigation Skip to search Skip to main content

YL201 Demonstrates Tolerability, Early Efficacy in Advanced Solid Tumors; Among 287 patients across multiple solid tumor indications, YL201 had an objective response rate of 40.8%, with a disease control rate of 83.6%.

Press/Media

Period7 Jul 2025

Media coverage

2

Media coverage

  • TitleYL201 Demonstrates Tolerability, Early Efficacy in Advanced Solid Tumors; Among 287 patients across multiple solid tumor indications, YL201 had an objective response rate of 40.8%, with a disease control rate of 83.6%.
    Media name/outletCancerNetwork
    Country/TerritoryUnited States
    Date7/07/25
    PersonsJennifer Yang
  • TitleYL201 Demonstrates Tolerability, Early Efficacy in Advanced Solid Tumors
    Media name/outletCancernetwork.com
    Country/TerritoryUnited States
    Date7/07/25
    URLct.moreover.com/?a=57159045833&p=1gw&v=1&x=R8EnlIcd7QJmgaocFi1vjQ
    PersonsJennifer Yang
View all 2
View less